The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended support to Bioneemtec India Private Limited, Chennaifor commercializing indigenous green chemistry technologies for the production of critical pharmaceutical ingredients and advanced drug delivery systems.

The project titled ‘Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes’ seeks tocontributing to import substitution, sustainable manufacturing, and healthcare security.

The project focuses on establishing advanced manufacturing capabilities for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and novel drug delivery systems through a combination of batch and continuous-flow chemistry technologies.

A key component of the project is the commercialization of an indigenous process for manufacturing Tranexamic Acid, an important therapeutic molecule used in the management of bleeding disorders. Developed using a cost-effective and environmentally responsible synthesis route, the technology is designed to deliver high-purity products while minimizing waste generation and process complexity. 

The project will also support the domestic production of Minoxidil and Dequalinium Chloride along with their key intermediates, strengthening local manufacturing capabilities in pharmaceutical value chains that presently depend substantially on imports. 

Bioneemtec has developed proprietary Drug Liposome APIs based on advanced nanotechnology platforms. These liposomal formulations are being developed for therapeutic applications including breast and skin cancer management and have demonstrated promising results with controlled nanoparticle characteristics. 

Rajesh Kumar Pathak, Secretary, TDB, stated, "The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility. Indigenous development of advanced APIs, critical intermediates, and novel drug delivery platforms will be instrumental in strengthening India's position as a global pharmaceutical manufacturing hub.”

“TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security,” added Pathak.

Expressing gratitude for the support, the leadership of Bioneemtec India Private Limited stated that the project will enable the company to scale up commercialization of its green chemistry-based manufacturing technologies and advanced pharmaceutical products.